In conclusion, the intraperitoneal injection of MCC950 can attenuate the progression of myopia in FDM by downregulating the expression levels of NLRP3 and its downstream signaling pathway factors (IL-1β, IL-18, Caspase-1, and MMP-2). Here, NLRP3 is linked to myopia.